PDS Biotechnology Corporation PDSB

Company Overview

PDS Biotechnology Corporation is a clinical-stage immunotherapy company focused on developing targeted cancer therapies and infectious disease vaccines. The company operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on immuno-oncology. Its core technology platform, Versamune®, is designed to activate tumor-specific T cells and enhance the body’s immune response against cancers and other diseases. PDS Biotechnology’s pipeline includes therapeutic candidates targeting human papillomavirus (HPV)-associated cancers, prostate cancer, and other solid tumors.

The company’s principal revenue drivers currently stem from collaboration agreements, licensing arrangements, and financing activities, as it has not yet commercialized an approved product. Its lead product candidate, PDS0101, has been evaluated in combination with immune checkpoint inhibitors and other therapies for HPV-positive cancers. PDS Biotechnology positions itself within the competitive immunotherapy market through its focus on T-cell activation and combination therapy strategies intended to improve clinical outcomes in difficult-to-treat cancers. Founded in 2005 and headquartered in Princeton, New Jersey, the company evolved from platform technology development into a clinical-stage oncology company listed on Nasdaq under the ticker PDSB.